Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
NDC API
0
VMF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 8-(4 (4-phenylbutoxy)benzoyl)amino-2-(tetrazol-5'-yl)-4-oxo-4h-1-benzopyran
2. Ono 1078
3. Ono-1078
4. Ono-rs 411
5. Ono-rs-411
6. Sb 205312
1. 103177-37-3
2. Azlaire
3. Ono-1078
4. Pranlukast Hydrate
5. Ono 1078
6. Sb 205312
7. Ccn 00401
8. Rs 411
9. Pranlukast (inn)
10. N-[4-oxo-2-(2h-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide
11. Onon
12. Ono-rs-411
13. 4-oxo-8-(4-(4-phenylbutoxy)benzoylamino)-2-(tetrazol-5-yl)-4h-1-benzopyran
14. Chembl21333
15. N-(4-oxo-2-(1h-tetrazol-5-yl)-4h-chromen-8-yl)-4-(4-phenylbutoxy)benzamide
16. Ccn-00401
17. Rs-411
18. Tb8z891092
19. Ncgc00181765-01
20. Sb-205312
21. Pranlukast [inn]
22. N-(4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl)-p-(4-phenylbutoxy)benzamide
23. N-(4-oxo-2-(2h-tetrazol-5-yl)-4h-chromen-8-yl)-4-(4-phenylbutoxy)benzamide
24. 8-[4(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4h-1-benzopyran;8-[4(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4h-1-benzopyran
25. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl]-p-(4-phenylbutoxy)benzamide;n-[4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl]-p-(4-phenylbutoxy)benzamide
26. Azlaire (tn)
27. Pranlukast [inn:ban]
28. Sr-05000001474
29. Unii-tb8z891092
30. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-chromen-8-yl]-4-(4-phenylbutoxy)benzamide
31. N-[4-oxo-2-(2h-tetrazol-5-yl)-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamide
32. Pranlukast [mi]
33. Pranlukast [mart.]
34. Schembl3693
35. Dsstox_cid_23782
36. Dsstox_rid_80074
37. Pranlukast [who-dd]
38. Dsstox_gsid_43782
39. Mls006010078
40. Gtpl3634
41. Ono Rs-411
42. Dtxsid3043782
43. Schembl18058592
44. Chebi:94810
45. Hms2089h16
46. Hms3650a14
47. Hms3714e03
48. Bcp04577
49. Hy-b0290
50. Zinc1542146
51. Tox21_112952
52. Ac-696
53. Bdbm50023198
54. Mfcd00864631
55. Akos015967342
56. Ccg-220661
57. Db01411
58. Sb19080
59. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamide
60. As-15105
61. Smr004701229
62. Cas-103177-37-3
63. Ft-0652673
64. P2115
65. C71133
66. D08408
67. Ab01275471-01
68. 177p373
69. L013134
70. Q7238392
71. Sr-05000001474-1
72. Sr-05000001474-2
73. Sr-05000001474-3
74. Brd-k97045029-001-01-9
75. Brd-k97045029-001-04-3
76. 8-[4-(4-phenylbutyloxy)benzoyl]amino-2-(tetrazol-5-yl)-4-oxo-4h-1-benzopyran
77. Benzamide, N-(4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl)-4-(4-phenylbutoxy)-
78. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl]-4(4-phenylbutoxy)benzamide
79. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-chromen-8-yl]-4-(4-phenyl-butoxy)-benzamide
80. Benzamide, N-(4-oxo-2-(2h-tetrazol-5-yl)-4h-1-benzopyran-8-yl)-4-(4-phenylbutoxy)-
81. Knt
82. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-chromen-8-yl]-4-(4-phenyl-butoxy)-benzamide (ono-rs-411)
83. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-chromen-8-yl]-4-(4-phenyl-butoxy)-benzamide(ono-rs-411)
Molecular Weight | 481.5 g/mol |
---|---|
Molecular Formula | C27H23N5O4 |
XLogP3 | 4.2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 9 |
Exact Mass | 481.17500423 g/mol |
Monoisotopic Mass | 481.17500423 g/mol |
Topological Polar Surface Area | 119 Ų |
Heavy Atom Count | 36 |
Formal Charge | 0 |
Complexity | 778 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists.
Pranlukast is a cysteinyl leukotriene receptor-1 antagonist.
Leukotriene Antagonists
A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level. (See all compounds classified as Leukotriene Antagonists.)
Anti-Asthmatic Agents
Drugs that are used to treat asthma. (See all compounds classified as Anti-Asthmatic Agents.)
R - Respiratory system
R03 - Drugs for obstructive airway diseases
R03D - Other systemic drugs for obstructive airway diseases
R03DC - Leukotriene receptor antagonists
R03DC02 - Pranlukast
Hepatic
Pranlukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Pranlukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
45
PharmaCompass offers a list of Pranlukast API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Pranlukast manufacturer or Pranlukast supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Pranlukast manufacturer or Pranlukast supplier.
PharmaCompass also assists you with knowing the Pranlukast API Price utilized in the formulation of products. Pranlukast API Price is not always fixed or binding as the Pranlukast Price is obtained through a variety of data sources. The Pranlukast Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Pranlukast manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pranlukast, including repackagers and relabelers. The FDA regulates Pranlukast manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pranlukast API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pranlukast manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pranlukast supplier is an individual or a company that provides Pranlukast active pharmaceutical ingredient (API) or Pranlukast finished formulations upon request. The Pranlukast suppliers may include Pranlukast API manufacturers, exporters, distributors and traders.
click here to find a list of Pranlukast suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Pranlukast Drug Master File in Japan (Pranlukast JDMF) empowers Pranlukast API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Pranlukast JDMF during the approval evaluation for pharmaceutical products. At the time of Pranlukast JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Pranlukast suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Pranlukast Drug Master File in Korea (Pranlukast KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Pranlukast. The MFDS reviews the Pranlukast KDMF as part of the drug registration process and uses the information provided in the Pranlukast KDMF to evaluate the safety and efficacy of the drug.
After submitting a Pranlukast KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Pranlukast API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Pranlukast suppliers with KDMF on PharmaCompass.
A Pranlukast written confirmation (Pranlukast WC) is an official document issued by a regulatory agency to a Pranlukast manufacturer, verifying that the manufacturing facility of a Pranlukast active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Pranlukast APIs or Pranlukast finished pharmaceutical products to another nation, regulatory agencies frequently require a Pranlukast WC (written confirmation) as part of the regulatory process.
click here to find a list of Pranlukast suppliers with Written Confirmation (WC) on PharmaCompass.
Pranlukast Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pranlukast GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pranlukast GMP manufacturer or Pranlukast GMP API supplier for your needs.
A Pranlukast CoA (Certificate of Analysis) is a formal document that attests to Pranlukast's compliance with Pranlukast specifications and serves as a tool for batch-level quality control.
Pranlukast CoA mostly includes findings from lab analyses of a specific batch. For each Pranlukast CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pranlukast may be tested according to a variety of international standards, such as European Pharmacopoeia (Pranlukast EP), Pranlukast JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pranlukast USP).